Home > Insider Trading > Filing (0001012975-19-000199)

Filing Details

Accession Number:: 0001012975-19-000199
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-02-26 21:08:47
Reporting Period:: 2019-02-22

Accepted Time:: 2019-02-26 21:08:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1656328	Sienna Biopharmaceuticals Inc.	SNNA	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219039	Keith Crandell	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1219042	Robert Nelsen	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1229592	Steven Gillis	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1757017	Arch Venture Fund X Overage, L.p.	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1768905	Arch Venture Partners X Overage, L.p.	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No
1769012	Arch Venture Partners X, Llc	8755 West Higgins Road Suite 1025 Chicago IL 60631	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-22	150,000	$2.50	2,900,575	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-02-22	150,000	$2.50	1,032,493	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-02-22	1,865,800	$2.50	1,865,800	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage").
The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The sole general Partner of ARCH X Overage is ARCH Venture Partners X Overage, L.P. ("AVP X Over GP"). The sole general partner of AVP X Over GP is ARCH Venture Partners X, LLC ("AVP X LLC"). AVP X Over LP and AVP X LLC may therefore be deemed to beneficially own the securities held by ARCH X Overage. AVP X Over GP and AVP X LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Keith L. Crandell, Robert Nelsen and Steven Gillis are managing directors of AVP X LLC, and they may be deemed to beneficially own the shares held by ARCH X Overage. Messrs. Crandell, Nelsen and Gillis disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.